Related Experiment Videos
Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D
Brendan Mulhern1, Joshua Pink2, Donna Rowen3
1Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia; School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK.
Summary
The NEWQOL-6D shows promise for assessing epilepsy quality of life, demonstrating better group validity than the EQ-5D-3L. Both tools offer some validity for economic evaluations in newly diagnosed focal epilepsy.
Area of Science:
- Neurology
- Health Economics
- Psychometrics
Background:
- Debate exists regarding the psychometric properties of the EQ-5D-3L for epilepsy assessment.
- The epilepsy-specific NEWQOL-6D was developed due to concerns about the EQ-5D-3L.
- Psychometric characteristics of the NEWQOL-6D have not been previously evaluated.
Purpose of the Study:
- To evaluate the validity and responsiveness of the EQ-5D-3L and NEWQOL-6D.
- To assess their utility in newly diagnosed focal epilepsy treatment evaluation.
Main Methods:
- Analysis of data from the Standard And New Antiepileptic Drugs trial.
- Assessment of convergent validity, known-group validity, and responsiveness.
- Evaluation of agreement between the EQ-5D-3L and NEWQOL-6D.
Main Results:
- Some convergence and agreement in utility scores, but divergence in descriptive systems.
- Both instruments showed known-group validity, with NEWQOL-6D having larger effect sizes for epilepsy-specific indicators.
- Responsiveness evidence was mixed, with varying standardized response means.
Conclusions:
- NEWQOL-6D tended to better reflect group differences, though without large absolute utility changes.
- Both EQ-5D-3L and NEWQOL-6D provide some evidence of validity for economic evaluations in newly diagnosed focal epilepsy.